drugset / Trial / NCT02508753

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753

Phase 1 Completed 52 enrolled Merck & Co., Inc.
RandomizedCrossoverDouble-blindOther

Summary

The purpose of the study is look at the possible side effects of two different doses of CXA-101/tazobactam, a low dose and a high dose, on participant's heart.

Timeline

Start
2010-06
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftolozane Small molecule 1000 mg Intravenous
Subject Ceftolozane Small molecule 3000 mg Intravenous
Comparator Moxifloxacin Small molecule 400 mg
Subject Tazobactam Small molecule 500 mg Intravenous
Subject Tazobactam Small molecule 1500 mg Intravenous

Indications

No indication recorded.